| Hazard Information | Back Directory | [Uses]
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1]. | [Enzyme inhibitor]
This intravenously administered anti-CD37 IgG fusion protein (MW = 107.5 kDa; CAS 1372645-37-8), also known by its code name TRU-016, is intended for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), as well as for autoimmune and inflammatory diseases. Otlertuzumab was created by humanizing SMIP-016, a mouse/human chimeric protein that demonstrates antitumor activity against lymphoid malignancies in preclinical studies, including in human B-cell tumor mouse xenograft models. TRU-016 demonstrates synergistic or additive activity in NHL cells in combination with rituximab, rapamycin, doxorubicin and bendamustine. In a phase I/II clinical trial in refractory or relapsed patients with CLL or small lymphocytic lymphoma, Otlertuzumab is well tolerated, with clinical benefit and a reduced absolute lymphocyte count observed in all cohorts dosed at > 0.1 mg/kg. TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especially patients refractory to standard treatment. | [in vivo]
Otlertuzumab (TRU-016) in combination with Bendamustine.html" class="link-product" target="_blank">Bendamustine (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice[2].
Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts[3]. | [References]
[1] Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. DOI:10.1182/blood-2013-07-512137
[2] Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571.
[3] Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|